Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’

• Type of Material: Article
• Authors: Toni K. Choueiri, Dana Farber Cancer Institute; J. Larkin, Royal Marsden NHS Foundation Trust; S. Pal, City Hope Comprehensive Cancer Center; R.J. Motzer, Memorial Sloan Kettering Cancer Center; B.I. Rini, Vanderbilt University; B. Venugopal, University of Glasgow; B. Alekseev, P. Hertsen Moscow Oncology Research Institute; H. Miyake, Hamamatsu University; G. Gravis, Aix Marseille Université; Mehmet Bilen, Emory University; S. Hariharan, Pfizer; A. Chudnovsky, Pfizer; K.A. Ching, Pfizer; X.J. Mu, Pfizer; M. Mariani, Pfizer; P.B. Robbins, Pfizer; B. Huang, Pfizer; A. Di Pietro, Pfizer; L. Albiges, Institut Gustave Roussy
• Language: English
• Date: 2021-08-30
• Publisher: ELSEVIER
• Publication Version: Final Published Version
• Copyright Statement: © 2021 The Author(s)
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.esmoop.2021.100177
• Title of Journal or Parent Work: ESMO OPEN
• Volume: 6
• Issue: 4
• Start Page: 100177
• End Page: 100177
• Keywords: Life Sciences & Biomedicine; Oncology; Science & Technology
• Research Categories: Health Sciences, Oncology; Biology, Cell

Abstract

The publisher regrets that some minor corrections to punctuation were missed in the typesetting process. In addition, Figure 3C was incorrect when the article was published. All corrections have now been applied to the article and the figure corrected. The corrected Figure 3C also appears below: [Figure presented] The publisher would like to apologise for any inconvenience caused.